The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives-Reference-Cited by-同舟云学术

The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives

Published:2021-01 Issue: Volume:157 Page:103199
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Brighi Nicole^ORCID,Conteduca Vincenza^ORCID,Lolli Cristian,Gurioli Giorgia,Schepisi Giuseppe,Palleschi Michela^ORCID,Mariotti Marita^ORCID,Casadei Chiara^ORCID,De Giorgi Ugo

Funder

AstraZeneca

Janssen Biotech

Pfizer

Roche Italia

Novartis

British Microcirculation Society

Ipsen

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference76 articles.

1. ANON Press release June 16, 2020: https://investor.lilly.com/news-releases/news-release-details/verzenior-abemaciclib-significantly-reduced-risk-cancer.

2. ANON Press release May 29, 2020: https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-Provides-Update-on-Phase-3-PALLAS-Trial-of-IBRANCE-palbociclib-Plus-Endocrine-Therapy-in-HR-HER2--Early-Breast-Cancer/default.aspx.

3. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: a comprehensive review;Assi;Crit. Rev. Oncol. Hematol.,2020

4. ECCO essential requirements for quality Cancer care: prostate cancer;Brausi;Crit. Rev. Oncol. Hematol.,2020

5. Spectrum and degree of CDK drug interactions predicts clinical performance;Chen;Mol. Cancer Ther.,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer;Cancer Research;2024-06-11

2. SHR and SCR coordinate root patterning and growth early in the cell cycle;Nature;2024-01-31

3. Recent progress and controversies in the treatment of metastatic hormone-sensitive prostate cancer;Journal of Men's Health;2024

4. Metastasiertes kastrationsresistentes Prostatakarzinom – Was kommt neues;Die Urologie;2023-11-13

5. Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide;Cancer Science;2023-11-03